Porosome reconstitution reverses Alzheimers in human brain organoids
Jena, B. P.; Cho, W. J.; Taatjes, D. J.; Patil, S. R.
Show abstract
A central challenge in overcoming diseases resulting from defects in the cellular nanoscale multiprotein porosome complexes, is the consequent alteration of other proteins within the complex. By exploiting the distinct porosomes present in different tissues, Porosome Therapeutics, Inc., has developed a clinically relevant approach to incorporate (reconstitute) functional wild type porosomes into the plasma membrane of diseased cells to overcome secretory defects. In a combinatorial strategy of reprogramming the neuronal secretory and metabolic components, we established a dual-target therapeutic framework that repairs synaptic and metabolic defects to counteract neurodegeneration in Alzheimers. Utilizing iPSC derived human brain organoids, as recommended by the NIH and FDA, we demonstrate both the morphological and functional reversal of Alzheimers following porosome-apigenin treatment. Using the UHD-CMOS-MEA System developed jointly by Sony Semiconductor Solutions (Sony), SCREEN Holdings (SCREEN) and VitroVo, we were able to monitor thousands of neuronal firing in the brain organoids, helping in assessing the restoration of neuronal function in Alzheimers following porosome-apigenin therapy.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A patient-derived blood-brain barrier model for screening copper bis(thiosemicarbazone) complexes as potential therapeutics in Alzheimer's disease 94%
- Glycated alpha-synuclein assemblies cause distinct Parkinsons disease pathogenesis in mice 93%
- Neurotransmitter loaded DNA nanocages as potential therapeutics for α-synuclein based neuropathies in cells and in vivo 92%
Similar papers in this journal
- New insights into the 17β-hydroxysteroid dehydrogenase type 10 and amyloid-β 42 derived cytotoxicity relevant to Alzheimer's disease 95%
- A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease 94%
- Comparison of plasma soluble and extracellular vesicles-associated biomarkers in Alzheimer’s Disease patients and cognitively normal individuals 94%
Similar papers in this journal
- High Content Screening and Proteomic Analysis Identify a Kinase Inhibitor that rescuespathological phenotypes in a Patient-Derived Model of Parkinson's Disease 92%
- Dopamine and cortical iPSC-derived neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunction: implications for protein deposition versus selective cell loss 92%
- TNFα increases Tyrosine Hydroxylase expression in human monocytes 92%
Similar papers in this journal
- Differential responses of primary neuron-secreted MCP-1 and IL-9 to type 2 diabetes and Alzheimer's disease-associated metabolites 94%
- Novel Adult Cortical Neuron Processing and Screening method illustrates Sex- and Age-dependent effects of pharmaceutical compounds 94%
- Improvement of glymphatic-lymphatic drainage of beta-amyloid by focused ultrasound in Alzheimer's disease model 94%